Artiva Biotherapeutics halts AlloNK trial and cuts 94% of staff after patient deaths
Artiva Biotherapeutics is ending development of its AlloNK cell therapy and laying off most employees after two patient deaths in a Phase 2a trial, one linked to chemotherapy neurotoxicity.
Artiva Biotherapeutics is halting its AlloNK cell therapy program and dismissing 94% of its workforce following two participant deaths in a clinical trial. The company paused its Phase 3 trial and a Phase 2a study after the U.S. Food and Drug Administration requested a halt to enrollment and dosing following notification of a fatality.
One death was directly linked to fludarabine chemotherapy used for patient conditioning, which caused a fatal neurological condition called leukoencephalopathy. Artiva reported this death to the FDA, which then asked the company to stop enrollment and dosing across the ongoing Phase 2a study. A second participant died approximately two months after starting treatment, but investigators determined this sudden death was unrelated to AlloNK or the study regimen.
Strategic retreat and financial strain
Artiva Biotherapeutics will stop developing its experimental AlloNK cell therapy for autoimmune conditions like rheumatoid arthritis. The company cited insufficient durability of clinical response for the decision. It is exploring strategic alternatives, including a potential merger, business combination, asset sale, or even dissolution and liquidation.
To preserve capital during this review, Artiva is cutting roughly 94% of its staff. The company had 115 employees as of June 30, meaning the layoffs could affect around 108 people and leave the business with fewer than 10. Artiva expects to complete the workforce reduction in the first quarter of 2027. The company hired Leerink Partners as its financial advisor for the strategic review.
Artiva's financial resources are dwindling. The company reported approximately $319.1 million in preliminary, unaudited cash, cash equivalents, and investments as of September 30. This was down from $349.1 million as of June 30. Artiva had raised $179 million in a 2024 upsized initial public offering and $300 million in an underwritten offering in May 2024.
Industry context and competitive pressure
The safety issues at Artiva follow similar clinical trial pauses by larger pharmaceutical companies developing cell therapies. Novartis and Bristol Myers Squibb each paused trials for their respective autologous cell therapies, rap-cel and zola-cel, due to safety concerns.
| Company | Therapy | Therapy Type | Safety Issue Reported |
|---|---|---|---|
| Novartis | rap-cel | Autologous | Three deaths from serious immune reactions |
| Bristol Myers Squibb | zola-cel | Autologous | One patient death 44 days after treatment |
| Artiva Biotherapeutics | AlloNK (AB-101) | Allogeneic (off-the-shelf) | One death from fludarabine neurotoxicity; one unrelated sudden death |
While the Novartis and Bristol Myers therapies are autologous, meaning they use a patient's own cells, Artiva's AlloNK is an allogeneic, off-the-shelf therapy derived from donor natural killer cells. Wall Street analysts have previously flagged the complex manufacturing process for autologous therapies as a possible contributor to safety issues. Artiva's case highlights that risks also exist in the conditioning chemotherapy regimens used alongside off-the-shelf approaches.
Artiva has canceled planned investor communications and scientific presentations. The company called off a November 9 investor webcast and withdrew clinical data submissions from the ACR Convergence 2026 conference. CEO Fred Aslan stated the company would detail the fludarabine-associated death in a scientific publication. "We will share findings from the fludarabine-associated death in a scientific publication given the treatment's widespread use in cell therapy conditioning regimens," Aslan said.
The company was evaluating AlloNK in combination with rituximab in a mid-stage basket trial for multiple inflammatory diseases, including rheumatoid arthritis, systemic sclerosis, and myositis. Artiva will complete its drastic workforce reduction in the first quarter of 2027 while its board explores strategic alternatives including a merger, asset sale, or dissolution.
